Business Context and Reporting Period
This Form 8-K is filed by Graybug Vision, Inc. (not Calcimedica, Inc.) on March 10, 2022. The report serves to announce the company's financial results for the full year ended December 31, 2021. Graybug Vision is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Market under the symbol GRAY.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the attached press release (Exhibit 99.1), which is referenced but not included in the provided text. Consequently, no specific financial figures can be extracted from this document alone.
Material Changes
The filing does not detail specific material changes or comparative data versus the prior period. It solely acts as a notification that the full-year 2021 results have been issued via a press release.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing the attached Exhibit 99.1 (Press Release), as they are absent from the 8-K text.
- Confirm the company name is Graybug Vision, Inc., noting the discrepancy with the "Calcimedica, Inc." label in the request metadata.
- Review the press release for any specific operational updates or strategic shifts for the 2021 fiscal year.
- Check the company's status as an emerging growth company for potential differences in financial reporting standards.